scholarly journals Low Doses of Venlafaxine in a Young Man with ASD and Behavioral Disorders: A Case Report

2016 ◽  
Vol 06 (01) ◽  
Author(s):  
G Galli Carminati ◽  
Samantha Perreaz ◽  
F Carminati
Keyword(s):  
Case Report ◽  
Behavioral Disorders ◽  
Low Doses

Adjunctive citalopram is effective on hallucinations and depersonalization symptoms: a case report

2004 ◽  
Vol 19 (3) ◽  
pp. 185-185 ◽  
Author(s):  
Vittorio Di Michele ◽  
Francesca Bolino
Keyword(s):  
Case Report ◽  
Weight Gain ◽  
Potential Interaction ◽  
The Body ◽  
Adjunctive Treatment ◽  
Low Doses ◽  
Safety And Efficacy ◽  
The Social ◽  
History Of ◽  
Comprehensive Rehabilitation

The treatment of depressive symptoms in patients affected by schizophrenia is often a concern for clinicians [2] due to potential interaction, in terms of safety and efficacy. Citalopram seems to be a safe SSRI as adjunctive treatment to Olanzapine because of the lack of interactions. We report a serendipitous finding showing that the adjunction of Citalopram to Olanzapine, led to disappearence of residual hallucinations and depersonalization symptoms in a few weeks.Mr A is a 27-year-old male, living in the community, with a 4-year history of schizophrenia,. He was treated with low doses of Olanzapine (10 mg/daily) since 2000 because of an intolerance to dose increments (weight gain and mydriasis).The persistence of sporadic hallucinations (commenting voices) and depersonalization symptoms (when he walked alone he felt his self leaving the body) was well tolerated by the patient. The social functioning was satisfactory: he had a protected job and was involved in a comprehensive rehabilitation programme.

Case Report of a Patient With Speech Delay and Behavioral Disorders Associated with Neuroblastoma. Possible Role of SMARCA4

2014 ◽  
Vol 207 (9) ◽  
pp. 455
Author(s):  
Anne-Sophie Defachelles ◽  
Nathalie Clément ◽  
Bénédicte Duban-Bedu ◽  
Françoise Boidein ◽  
Gaëlle Pierron ◽  
...  
Keyword(s):  
Case Report ◽  
Behavioral Disorders ◽  
Speech Delay

scholarly journals Malignant catatonia responsive to low doses of lorazepam: case report

2015 ◽  
Vol 134 (2) ◽  
pp. 176-179
Author(s):  
Diego Fernando Moreira Matias ◽  
Sabrina de Mello Ando ◽  
Rachel Riera ◽  
Aécio Flávio Teixeira de Góis
Keyword(s):  
Case Report ◽  
Early Intervention ◽  
Early Diagnosis ◽  
Psychiatric Disorders ◽  
Clinical Outcomes ◽  
High Fever ◽  
Low Doses ◽  
Fatal Complication ◽  
Autonomic Instability ◽  
Malignant Catatonia

Abstract CONTEXT: Catatonia can be divided into non-malignant or malignant. The latter is characterized by autonomic instability, exhibiting high fever, tachycardia and hypertension, and is regarded as a fulminant and rapidly progressive subtype. CASE REPORT: This article reports a case of malignant catatonia in a 43-year-old patient who had been presenting psychiatric disorders for the last three years. The patient was stable, maintaining mutism, immobility and autonomic abnormalities. Oral lorazepam (1 mg every eight hours) was introduced and, in a few hours, the patient became afebrile. Two days later, the patient was already responding to verbal commands. CONCLUSIONS: Early intervention with lorazepam reduced the evolution of this patient to a fatal complication. Therefore, this case report sought to show that early diagnosis and intervention reduced the occurrence of serious and irreversible clinical outcomes.

scholarly journals Acute psychosis due to brucellosis in a rural Iran: a report of two cases

2013 ◽  
Vol 2 (1) ◽  
pp. 29-31 ◽  
Author(s):  
R Bidaki ◽  
SM Yassini ◽  
MT Maymand ◽  
M Mashayekhi ◽  
S Yassini
Keyword(s):  
Case Report ◽  
Behavioral Disorders ◽  
Auditory Hallucination ◽  
Rare Condition ◽  
Zoonotic Disease ◽  
Psychotic Symptoms ◽  
Psychotic Depression ◽  
Acute Psychosis ◽  
Systemic Involvement ◽  
Endemic Areas

Introduction: Brucellosis is a zoonotic disease that causes multi systemic involvement. Neurobrucellosis occurs in less than 5% of patients. Psychosis as a presentation of neuro-brucellosis is a rare condition. Case Report: We report a woman that was referred because of psychotic depression following brucellosis. Also we present a 66-year-old man that was admitted because of acute psychotic symptoms. He had behavioral disorders, visual and auditory hallucination, restlessness, impulsivity, incoherency and episodic crying. Neurobrucellosis was confirmed. Conclusion: In patients with atypical psychosis in endemic areas, physicians should consider the portability of brucellosis. DOI: http://doi.dx.org/10.3126/ijim.v2i1.8007 Int J Infect Microbiol 2013;2(1):29-31

Pulmonary Toxicity Caused by Low Doses of Amiodarone-Case Report

CHEST Journal ◽  
2015 ◽  
Vol 148 (4) ◽  
pp. 388A ◽  
Author(s):  
Romana Susa ◽  
Zorica Lazic ◽  
Bojan Djokic ◽  
Vojislav Cupurdija
Keyword(s):  
Case Report ◽  
Pulmonary Toxicity ◽  
Low Doses

Neurotoxic Syndrome Associated with Risperidone and Fluvoxamine

2002 ◽  
Vol 36 (3) ◽  
pp. 440-443 ◽  
Author(s):  
Roy R Reeves ◽  
James E Mack ◽  
John J Beddingfield
Keyword(s):  
Differential Diagnosis ◽  
Case Report ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Syndrome ◽  
Adverse Reactions ◽  
African American Woman ◽  
American Woman ◽  
Signs And Symptoms ◽  
Concomitant Treatment ◽  
Low Doses

OBJECTIVE: To report a case of a neurotoxic syndrome in a patient undergoing concomitant treatment with risperidone and fluvoxamine. CASE REPORT: A 24-year-old African American woman hospitalized for psychosis was unresponsive to risperidone. Because of obsessive symptoms, low doses of fluvoxamine were added to her treatment regimen. Within 2 days, she developed confusion, diaphoresis, diarrhea, hyperreflexia, and myoclonus, which then progressed to rigidity, fever, and unresponsiveness, requiring endotracheal intubation. Symptoms resolved over 10 days with discontinuation of medication, hydration, and bromocriptine 5 mg 3 × daily. Ultimately, she was treated with olanzapine and fluvoxamine without adverse effects. DISCUSSION: This represents the first reported case of a neurotoxic syndrome secondary to treatment with risperidone and fluvoxamine. Differential diagnosis between neuroleptic malignant syndrome (NMS) and serotonin syndrome (SS) could not be accurately determined because of the overlap of signs and symptoms of both syndromes. NMS and SS may represent different aspects of a more generalized neurotoxic syndrome. This could be an important consideration in formulating treatment for neurotoxic syndromes. CONCLUSIONS: Clinicians should be aware of potentially serious adverse reactions that may occur during concomitant treatment with antipsychotics and selective serotonin-reuptake inhibitors.

scholarly journals Maintenance Electroconvulsive Therapy Meeting Unmet Needs of Antipsychotics in Older Patients: A Case Report

2020 ◽  
pp. 1-3
Author(s):  
Sharmilla Kanagasundram ◽  
Ishwary Damodaran ◽  
Lee Wen Pei ◽  
Sharmilla Kanagasundram ◽  
Tan Chow Hock
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Electroconvulsive Therapy ◽  
Older Patients ◽  
Unmet Needs ◽  
First Episode ◽  
Low Doses ◽  
Extrapyramidal Side Effects ◽  
Anticholinergic Side Effect ◽  
Maintenance Ect

This case report highlights problems encountered by psychiatrists when treating a 68-year-old female patient who presented with a first episode of psychosis. She suffered from constipation, an anticholinergic side effect of quetiapine and both anticholinergic and extrapyramidal side effects of olanzapine. Finally, she was able to tolerate a combination of two pharmacologically different antipsychotics namely olanzapine and aripiprazole combined with a course of ECT followed by maintenance ECT. The authors would like to highlight maintenance ECT as part of the solution to patients who find it difficult to tolerate antipsychotics. Especially when only low doses of antipsychotics can be tolerated by the patient.

The treatment of autism with pipamperone: A case report

2016 ◽  
Vol 33 (S1) ◽  
pp. S549-S549
Author(s):  
B. Petrosino ◽  
M.S. Signorelli ◽  
F. Magnano di San Lio ◽  
C. Petrosino ◽  
E. Aguglia
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Social Functioning ◽  
Behavioral Disorders ◽  
Autism Spectrum ◽  
Severe Mental Retardation ◽  
Extrapyramidal Side Effects ◽  
Psychomotor Agitation ◽  
Self Injury ◽  
Spectrum Disorders

IntroductionAdults with autism spectrum disorders (ASD) often have behavioral disorders, like aggression, agitation and self-injury. These problems are frequently severe enough to limit educational and developmental progress. Only risperidone and aripiprazole have so far been approved by the FDA for the treatment of behavioral disturbance associated with autism. These drugs are not very effective in the long term, with little benefits to the social functioning and they are associated with side effects. This case report describes the use of pipamperone, in treating behavioral disorders of a patient with autism spectrum disorder and severe mental retardation.Case presentationHere is presented the case of a 32-year-old man with autism spectrum disorder, severe mental retardation (caused by undiagnosed phenylketonuria for the first 3 years of life) treated with antipsychotics since childhood. He showed numerous episodes of psychomotor agitation, hetero-direct physical aggression and self-injury, and movement disorders induced by drugs. Treatment with pipamperone reduced drastically crises of psychomotor agitation, and behavioral disorders, without extrapyramidal side effects, and led to an improvement in social functioning. The control of behavioral symptoms associated with adherence to treatment was maintained for 6-month follow up. These clinical observations are supported by ratings using: ABC, CGI-S and CGI-I, VABS, SAS, AIMS.ConclusionThis case report provides the first potential evidence that pipamperone may be effective in treating behavioral problems associated with autism spectrum disorders. Moreover, the improvement of social functioning and the lack of extrapyramidal side effects make this drug notable for its effectiveness and tolerability.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Sign in / Sign up

Export Citation Format

Share Document